Minakem obtained €14.5 million investment from its parent company

| By | API, Investments, Pharmaceutical Manufacturing
0
355

Minakem, a contract manufacturing company, specialized in custom development and manufacturing of building blocks, intermediates and Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, received a €14.5 million investment from parent company Minafin.

The company will use the funds to continue to extend its manufacturing capacity at its Dunkirk site in France. It will enable Minakem to set up a new production line, increasing production capacity.

In parallel, existing production assets are being upgraded in order to increase flexibility. This will free up an additional production volume. In total, the production volume at the Dunkirk site will increase by 54 cubic meters to a total capacity of 148 cubic meters.

Led by Thierry van Nieuwenhove, CEO, Minakem is a fine chemical company with operations at three facilities located in Dunkirk (FR), Beuvry la Foret (FR) and Louvain-la-Neuve (BE) and expertise in complex multi-step synthesis, pressure chemistry, chiral synthesis, halogenation chemistry, steroid chemistry and ‘prazole’ chemistry.

SOURCE: finsmes
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.